undamentalytics Newsletter
Sign in

Utah Medical Products Inc (UTMD) stock

Add to watchlist

Add holding +

NASDAQ: UTMD Nasdaq Health Care Equipment Next results ~January 28, 2027

B+ Fundamentals grade

Utah Medical Products Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$93

Cash-flow model

Base case. Range ~$77–$110 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 32% above it.

Price used: $70.55, November 2, 2026

Utah Medical Products Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds55 adding, 44 cuttingOf 16 active managers that changed their stake, 8 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Utah Medical Products files

Where Utah Medical Products stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $36m, down 7.0% on a year earlier, a steeper fall than the 4.4% decline a quarter earlier. That puts it 92 of 103 for growth among the health care equipment companies we cover. Free-cash-flow margin fell to 31.7% from 35.5% a year earlier. Operating margin narrowed to 28.4% from 32.5%. The diluted share count is down 4.8% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades B+. It passes 7 of our 7 financial-health checks. Our cash-flow model value is $93.08 a share, against a share price of $68.12. At that price, our model says the market is pricing in cash flow shrinking about 6.2% a year for five years, close to the -5.9% a year revenue growth it has delivered.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 28, 2027 (estimated)

Utah Medical Products Inc's trailing-twelve-month revenue fell 7.0% year on year, with a free-cash-flow margin of 31.7%. Where it stands out: free-cash-flow margin of 31.7% ranks 2 of 128 health care equipment companies we cover. Where it lags: revenue growth of -7.0% ranks 112 of 129 health care equipment companies we cover.

Our discounted-cash-flow model values the business at ~$93 per share in the base case (~$77–$110 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Operating margin compressing: TTM operating margin fell to 28.4%, down 4.1pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $70.55 is 32% below our value per share of $93.
  • High operating margin. 28.4% of revenue is left as operating profit, against a median of -8.3% for health care equipment companies we cover.
  • Strong cash generation. 31.7% of revenue turned into free cash flow, against a median of -3.4% for health care equipment companies we cover.
  • Shrinking share count. Diluted shares fell 4.8% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Revenue shrinking. Revenue fell 7.0% over the last 12 months.
  • Margins narrowing. Operating margin is down 4.1 points on a year ago.
  • Growth easing. The growth rate is 2.6 points lower than a quarter earlier.

Latest results: FY2026 Q2

Filed August 12, 2026
Revenue
$9m, down 14.3% on a year earlier
Share reaction
-0.7% in the first session after the results on October 22, 2026, against -1.7% for the S&P 500
Next report
October 22, 2026

Utah Medical Products' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.6%
  • 1 week-4.0%
  • 1 month-4.8%
  • This year+27.8%
  • 1 year+23.8%
  • 5 years-23.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$36.1M
Operating margin
28.4%
Net margin
29.0%
EPS (TTM, diluted)
$3.28

Growth

Revenue growth
−7.0%
Change in growth rate
−2.6 pts
Share count change
−4.8%

Cash

Free cash flow (TTM)
$11.4M
FCF margin
31.7%
Stock pay % of revenue
1.1%

Earnings

Last results
October 22, 2026
Next results (est.)
January 28, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Utah Medical Products Inc valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 5.2% a year for five years.That is close to the -5.9% a year revenue growth Utah Medical Products has delivered.

  • Priced in-5.2%
  • Last 12 months-7.0%
  • 3 years a year-11.4%
  • 5 years a year-5.9%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($70.55, Nov 2, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$93
Price used
$70.55close November 2, 2026
Implied change
▲ +32%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Utah Medical Products Inc's free cash flow after stock-based pay with after-tax interest added back ($12.6M, FY2026 Q2 TTM), growing 2% a year for five years and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$77–~$110 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Utah Medical Products Inc's free cash flow after stock-based pay ( $12.6M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Utah Medical Products Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.79 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$93 ~$77–$110 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$61 ~$63–$110 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$59 ~$42–$84 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$65 ~$55–$80 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$74 ~$59–$93 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Utah Medical Products Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −17%
  • Revenue growth 5 points higher ▲ +23%
  • Free-cash-flow margin 1 point lower ▼ −2%
  • Last year's free-cash-flow margin change, if it persists ▼ −8%
  • Discount rate 1 point higher ▼ −10%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $85$105$132$168$214$274
8.5% $71$86$105$131$164$207
10% $63$75$90$109$134$167

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$49.14$62.07$70.51$72.80$95.70$75.73$92.37$94.09$79.88$59.36$55.20$70.55
Market value$185m$234m$264m$273m$358m$278m$338m$343m$291m$208m$179m$225m
+ Net debt (− = net cash)−$23m−$26m−$40m−$51m−$43m−$52m−$61m−$75m−$93m−$83m−$86m−$87m
Enterprise value$162m$207m$224m$222m$315m$226m$277m$268m$198m$125m$93m$138m
Multiples
Price / sales 4.6x5.9x6.4x6.5x7.6x6.6x6.9x6.6x5.8x5.1x4.6x6.2x
Price / earnings 15.7x19.3x31.0x14.7x24.3x25.8x22.9x20.8x17.5x15.0x15.8x21.5x
Price / free cash flow 13.6x20.8x17.2x16.6x21.7x14.4x16.4x16.9x13.4x14.2x12.5x19.7x
EV / EBITDA 10.0x12.4x11.4x11.4x17.2x15.8x14.2x13.1x11.4x8.7x7.6x12.4x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

100 /100

Strong moat

How hard Utah Medical Products's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Net income has been a median 12.1% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 61.8%, moving by 2.0 percentage points (standard deviation) across 10 years.

  • Durability 20 / 20

    Operating margin has been a median 36.3%; its worst year was 28.4%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 37.5% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 12.6% over five years; stock-based pay has been a median 0.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Utah Medical Products Inc: too few analysts cover it.

Positioning

Short interest
5.4%
of tradable shares
Days to cover
3.76
at average volume
Short interest, 1 month
−19%
to October 15, 2026
Held by institutions
77%
of shares
Held by insiders
7.2%
of shares
Employees
140
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +23.8%

$57.00 on October 31, 2025 to $70.55

ThenNowEffect
Revenue (last 12 months) $39m $36m −7.0%
Net margin 32.3% 29.0% −10.2%
P/E multiple 15.2x 21.5x +41.1%
Share count 3m 3m +5.0%

Biggest factor: p/e multiple.

Last 3 years −7.8%

$76.54 on November 3, 2023 to $70.55

ThenNowEffect
Revenue (last 12 months) $52m $36m −30.5%
Net margin 33.2% 29.0% −12.6%
P/E multiple 16.1x 21.5x +33.3%
Share count 4m 3m +13.8%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
UTMD+22%+2%−15%−26%−7%+28%
Industry peers (median)−9%−37%−8%−19%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
UTMD58%58%42%33%33%82%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
UTMD−26%−19%−23%−26%−19%−13%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 56% from November 22, 2021 to April 30, 2025. Getting back needed a 125% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$52.78 – $76.66
From 52-week high
−8.0%
vs 50-day average
−3.1%
vs 200-day average
+4.3%
Volatility (1 year)
29%
Beta vs S&P 500
0.20

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±1.9%
After a week
5 up, 7 down
typical move ±4.5%
After a month
6 up, 5 down
typical move ±6.5%
Results releasedNext dayS&P 500 next day5 days21 days
October 22, 2026 −0.7% −1.7% −10.6% —
July 23, 2026 −3.0% −1.1% +0.5% +3.4%
April 23, 2026 −3.5% +0.4% −6.0% −7.4%
January 29, 2026 +0.4% −0.5% +3.3% +10.3%
October 23, 2025 −1.0% +1.4% −7.2% −9.6%
July 24, 2025 +0.6% +0.5% −4.4% +4.8%
April 29, 2025 −0.9% +0.7% +2.5% +4.5%
January 28, 2025 −4.5% +0.4% −6.5% −6.9%
October 29, 2024 −0.3% −0.1% −0.4% +1.4%
January 30, 2024 −4.3% −1.7% −9.4% −15.2%
October 26, 2023 −3.1% −1.6% +0.5% +5.2%
July 25, 2023 0.0% +0.3% +2.9% −2.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Utah Medical Products Inc in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Utah Medical Products Inc
$35M $40M $45M $50M $55M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $51.5M Revenue (TTM), FY23 Q4: $50.2M Revenue (TTM), FY24 Q1: $49M Revenue (TTM), FY24 Q2: $46.6M Revenue (TTM), FY24 Q3: $44.1M Revenue (TTM), FY24 Q4: $40.9M Revenue (TTM), FY25 Q1: $39.3M Revenue (TTM), FY25 Q2: $38.8M Revenue (TTM), FY25 Q3: $38.6M Revenue (TTM), FY25 Q4: $38.5M Revenue (TTM), FY26 Q1: $37.5M Revenue (TTM), FY26 Q2: $36.1M $36.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $51.5M
FY23 Q4 $50.2M
FY24 Q1 $49M
FY24 Q2 $46.6M
FY24 Q3 $44.1M
FY24 Q4 $40.9M
FY25 Q1 $39.3M
FY25 Q2 $38.8M
FY25 Q3 $38.6M
FY25 Q4 $38.5M
FY26 Q1 $37.5M
FY26 Q2 $36.1M
Revenue growth, TTM YoY Utah Medical Products Inc
-20% -15% -10% -5% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -0.3% Revenue growth, TTM YoY, FY23 Q4: -3.9% Revenue growth, TTM YoY, FY24 Q1: -6.5% Revenue growth, TTM YoY, FY24 Q2: -10.3% Revenue growth, TTM YoY, FY24 Q3: -14.4% Revenue growth, TTM YoY, FY24 Q4: -18.6% Revenue growth, TTM YoY, FY25 Q1: -19.9% Revenue growth, TTM YoY, FY25 Q2: -16.6% Revenue growth, TTM YoY, FY25 Q3: -12.4% Revenue growth, TTM YoY, FY25 Q4: -5.8% Revenue growth, TTM YoY, FY26 Q1: -4.4% Revenue growth, TTM YoY, FY26 Q2: -7.0% -7.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -0.3%
FY23 Q4 -3.9%
FY24 Q1 -6.5%
FY24 Q2 -10.3%
FY24 Q3 -14.4%
FY24 Q4 -18.6%
FY25 Q1 -19.9%
FY25 Q2 -16.6%
FY25 Q3 -12.4%
FY25 Q4 -5.8%
FY26 Q1 -4.4%
FY26 Q2 -7.0%
Operating margin (TTM) Utah Medical Products Inc
28% 30% 32% 34% 36% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 34.8% Operating margin (TTM), FY23 Q4: 33.4% Operating margin (TTM), FY24 Q1: 33.1% Operating margin (TTM), FY24 Q2: 32.7% Operating margin (TTM), FY24 Q3: 33.1% Operating margin (TTM), FY24 Q4: 33.2% Operating margin (TTM), FY25 Q1: 32.8% Operating margin (TTM), FY25 Q2: 32.5% Operating margin (TTM), FY25 Q3: 30.8% Operating margin (TTM), FY25 Q4: 29.6% Operating margin (TTM), FY26 Q1: 28.8% Operating margin (TTM), FY26 Q2: 28.4% 28.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 34.8%
FY23 Q4 33.4%
FY24 Q1 33.1%
FY24 Q2 32.7%
FY24 Q3 33.1%
FY24 Q4 33.2%
FY25 Q1 32.8%
FY25 Q2 32.5%
FY25 Q3 30.8%
FY25 Q4 29.6%
FY26 Q1 28.8%
FY26 Q2 28.4%
FCF margin (TTM) Utah Medical Products Inc
30% 35% 40% 45% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 42.8% FCF margin (TTM), FY23 Q4: 43.1% FCF margin (TTM), FY24 Q1: 40.8% FCF margin (TTM), FY24 Q2: 38.8% FCF margin (TTM), FY24 Q3: 38.4% FCF margin (TTM), FY24 Q4: 35.7% FCF margin (TTM), FY25 Q1: 34.7% FCF margin (TTM), FY25 Q2: 35.5% FCF margin (TTM), FY25 Q3: 35.9% FCF margin (TTM), FY25 Q4: 37.2% FCF margin (TTM), FY26 Q1: 34.7% FCF margin (TTM), FY26 Q2: 31.7% 31.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 42.8%
FY23 Q4 43.1%
FY24 Q1 40.8%
FY24 Q2 38.8%
FY24 Q3 38.4%
FY24 Q4 35.7%
FY25 Q1 34.7%
FY25 Q2 35.5%
FY25 Q3 35.9%
FY25 Q4 37.2%
FY26 Q1 34.7%
FY26 Q2 31.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Utah Medical Products took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $38.5M
  2. Other income $2.7M · 7.0%
  3. Cost of revenue $16.5M · 42.9%
  4. Gross profit $22M · 57.1%
  5. Research and development $668,000 · 1.7%
  6. Selling, general and admin $9.9M · 25.8%
  7. Operating income $11.4M · 29.6%
  8. Income tax $2.8M · 7.3%
  9. Net income $11.3M · 29.3%

Shares of revenue. Source: Utah Medical Products's 10-K for FY2025, as filed with the SEC. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 26 25 38 42 40 41 40 39 41 42 47 42 49 52 50 41 39 36
Gross profit 14 13 22 25 24 25 24 24 26 26 29 26 31 32 30 24 22 21
EBITDA 10 9 13 16 15 17 16 17 20 19 18 14 20 20 17 14 12 11
Operating income 9 9 12 15 15 16 16 16 19 19 18 14 19 20 17 14 11 10
Net income 6 6 7 10 11 11 12 12 9 19 15 11 15 16 17 14 11 10
Diluted EPS $1.72 $1.65 $2.03 $2.74 $3.02 $3.02 $3.14 $3.22 $2.28 $4.95 $3.94 $2.94 $4.04 $4.52 $4.57 $3.96 $3.48 $3.28
Growth (year on year)
Revenue — −3.1% +50.7% +9.8% −2.5% +1.9% −2.7% −2.1% +5.4% +1.4% +11.7% −10.1% +16.3% +6.6% −3.9% −18.6% −5.8% −7.0%
EBITDA — −5.0% +32.3% +26.3% −2.6% +9.1% −3.4% +3.2% +17.1% −1.1% −5.8% −21.7% +35.9% +4.5% −14.7% −17.7% −14.6% −17.3%
Operating income — −5.4% +32.7% +28.3% −2.4% +9.3% −3.4% +3.4% +17.4% −1.7% −5.7% −22.3% +37.7% +4.8% −15.2% −19.0% −16.1% −18.7%
Net income — −3.9% +23.3% +37.2% +12.2% −0.2% +4.1% +2.4% −29.9% +118.2% −20.6% −26.7% +37.0% +11.4% +1.0% −16.6% −18.7% −16.5%
Diluted EPS — −4.1% +23.0% +35.0% +10.2% 0.0% +4.0% +2.5% −29.2% +117.1% −20.4% −25.4% +37.4% +11.9% +1.1% −13.3% −12.1% −12.3%
Margins
Gross margin 53.2% 52.6% 59.2% 60.9% 59.9% 60.5% 60.2% 60.3% 63.7% 62.6% 62.8% 60.6% 63.0% 61.6% 59.8% 59.0% 57.1% 57.9%
EBITDA margin 38.5% 37.8% 33.1% 38.1% 38.1% 40.8% 40.5% 42.7% 47.5% 46.3% 39.1% 34.1% 39.8% 39.0% 34.6% 35.0% 31.7% 30.8%
Operating margin 36.4% 35.5% 31.3% 36.6% 36.6% 39.3% 39.0% 41.2% 45.9% 44.5% 37.6% 32.5% 38.5% 37.9% 33.4% 33.2% 29.6% 28.4%
Net margin 24.1% 23.9% 19.6% 24.5% 28.2% 27.6% 29.5% 30.9% 20.5% 44.2% 31.4% 25.6% 30.1% 31.5% 33.1% 33.9% 29.3% 29.0%
Free-cash-flow margin 26.1% 22.4% 29.4% 32.0% 29.6% 34.6% 33.9% 28.6% 37.0% 39.1% 35.2% 45.7% 42.1% 38.9% 43.1% 35.7% 37.2% 31.7%
Cash flow
Cash from operations 7 7 11 14 12 15 14 15 17 17 17 20 21 21 22 15 15 12
Capital spending 0 2 0 0 0 1 0 3 2 0 1 1 1 1 1 0 0 0
Free cash flow 7 6 11 13 12 14 14 11 15 16 17 19 21 20 22 15 14 11
Stock-based pay 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Free cash flow after stock pay 7 6 11 13 12 14 14 11 15 16 16 19 20 20 21 14 14 11
Balance sheet
Cash 0 4 7 9 14 19 23 26 40 51 43 52 61 75 93 83 86 88
Total debt 0 1 22 13 9 5 0 — 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −0 −3 15 4 −5 −14 −23 −26 −40 −51 −43 −52 −61 −75 −93 −83 −86 −87
Diluted shares — 4m 4m 4m 4m 4m 4m 4m 4m 4m 4m 4m 4m 4m 4m 4m 3m 3m
Returned to shareholders
Dividends 3 6 3 4 4 4 4 4 3 4 4 4 11 3 4 4 4 4
Buybacks — — — — — — — — 0 1 0 7 0 2 0 20 8 2
Total returned 3 6 3 4 4 4 4 4 3 5 5 11 11 6 4 24 12 6

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

7 of 7 checks passed · June 30, 2026
What it owns · $125m
Short-term assets $101mLonger-term assets $24m
What it owes, and who funded it · $125m
Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $122m
  • Short-term assets cover short-term liabilities $101m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $101m short-term assets against $469,000 of longer-dated liabilities.
  • More cash than debt $88m of cash against $195,000 of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt $12m of operating cash flow against $195,000 of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Utah Medical Products Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$1.9M
Dividends (TTM)
$3.9M
Returned to shareholders
51%
of free cash flow
Buybacks, last 3 fiscal years
$28.3M
Diluted share count
−4.8%
year over year
Total shareholder yield
2.6%
dividends 1.8% + buybacks 0.8% of market value
Dividend payout ratio
38%
of net income paid out
R&D spending
1.9%
of revenue
Days sales outstanding
36 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated UTMD ECOR CTSO RVP OBIO POCI Median
Revenue, last 12 months $36m $37m $37m $34m $32m $32m $99m
Revenue growth, last 12 months −7.0% 33.5% 3.1% −11.2% 986.1% 65.2% 9.2%
Revenue growth, 3-year average −11.4% 50.4% 0.8% −14.7% 94.5% 14.4% 13.5%
Revenue growth, latest quarter −14.3% 28.0% 0.2% −31.1% −89.5% 42.0% 10.2%
Gross margin 57.9% 87.1% 71.6% −1.4% 99.5% 17.2% 61.2%
Operating margin 28.4% −37.6% −34.7% −66.9% −181.4% −11.1% −8.5%
Operating margin, 3-year average 31.2% −51.0% −49.7% −52.5% <−999% −18.2% −17.9%
Net margin 29.0% −40.0% −48.9% −9.9% −184.6% −11.5% −12.0%
Cash from operations / revenue 32.8% −26.3% −24.6% −14.6% −182.4% −4.9% −1.9%
Free-cash-flow margin 31.7% −26.4% −25.0% −37.7% −184.8% −5.8% −3.9%
Free-cash-flow margin, 3-year average 35.4% <−999% −37.9% −20.6% <−999% −13.4% −7.0%
Stock pay / revenue 1.1% 7.2% 6.1% 10.7% 34.8% 3.5% 6.1%
Change in share count −4.8% 8.5% 4.1% 0.0% 58.1% 25.6% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -7.0% 9.1% 112 of 129
Change in growth rate Growth -2.6pp -0.6pp 90 of 129
Gross margin Profitability 57.9% 61.9% 72 of 123
Operating margin Profitability 28.4% -8.3% 6 of 132
Net margin Profitability 29.0% -12.0% 4 of 133
Free-cash-flow margin Cash generation 31.7% -3.4% 2 of 128
Stock pay as % of revenue Cash generation 1.1% 6.1% 10 of 123
Long-term debt as % of assets Balance sheet 0.2% 24.2% 8 of 87
Change in share count Balance sheet -4.8% 3.3% 7 of 115
Days sales outstanding Balance sheet 36 days 57 days 14 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$160M
Institutions reporting
114
Shares held vs prior quarter
▲ 2.3%
Positions opened / closed
7 / 10

Top buyers and sellers, Q2 2026: 55 institutions bought and 44 sold ; the biggest buyer was Brandes Investment Partners, LP (+26K shares) and the biggest seller Geode Capital Management, LLC (−12K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Brandes Investment Partners, LP $32.8M 475K 20.5% ▲ 5.8%
Blackrock, Inc. $14.1M 204K 8.8% ▲ 8.5%
Dimensional Fund Advisors LP $13.7M 199K 8.6% ▲ 0.5%
Renaissance Technologies LLC $12.1M 176K 7.6% ▼ 4.5%
Vanguard Capital Management LLC $9.3M 135K 5.8% ▼ 2.9%
Geode Capital Management, LLC $7.5M 108K 4.7% ▼ 10.0%
Minerva Advisors LLC $6.5M 94K 4.0% 0.0%
Hotchkis & Wiley Capital Management LLC $5.9M 85K 3.7% ▼ 4.4%
Rice Hall James & Associates, LLC $4.9M 71K 3.1% ▲ 5.1%
Morgan Stanley $4.8M 70K 3.0% ▲ 42.8%
State Street Corp $4.4M 64K 2.8% ▼ 0.7%
Quantinno Capital Management LP $3M 43K 1.9% ▲ 44.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Utah Medical Products Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 28, 2027 estimated from the company's past filing pattern, not announced

  • October 22, 2026
  • July 23, 2026
  • April 23, 2026
  • January 29, 2026
  • October 23, 2025
  • July 24, 2025

Recent SEC filings

Data status

When each part of this page on Utah Medical Products Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Utah Medical Products Inc in brief

What does Utah Medical Products Inc do?
Utah Medical Products Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Utah Medical Products Inc's stock ticker?
Utah Medical Products Inc trades under the ticker UTMD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Utah Medical Products Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Utah Medical Products Inc reported revenue of $36.1M, 7.0% lower than a year earlier, according to its SEC filings.
What is Utah Medical Products Inc's free cash flow?
Utah Medical Products Inc's free-cash-flow margin is 31.7% of revenue over the trailing twelve months, ranking 2 of the 128 health care equipment companies we cover.
What is Utah Medical Products Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Utah Medical Products Inc's free cash flow after stock-based pay gives ~$93 per share in the base case, and ~$77–$110 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Utah Medical Products Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Brandes Investment Partners, LP, Blackrock, Inc. and Dimensional Fund Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Utah Medical Products Inc buying back stock, and does it pay a dividend?
Utah Medical Products Inc spent $1.9M on share repurchases over the trailing twelve months, and its diluted share count fell 4.8% over the year.
What is Utah Medical Products Inc's market cap?
On November 2, 2026, Utah Medical Products Inc's market capitalisation was about $225M, with a price-to-earnings ratio of 21.5 and net debt of -$87.3M. Market figures come from third-party market data and may be delayed.
Does Utah Medical Products Inc pay a dividend?
Yes: Utah Medical Products Inc paid $3.9M in dividends over the trailing twelve months, a dividend yield of 1.75% and a payout ratio of 37.6%.
How much debt does Utah Medical Products Inc have?
Utah Medical Products Inc's debt-to-equity ratio is 0.2%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Utah Medical Products Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Utah Medical Products Inc are Electrocore, Inc., Cytosorbents Corp, Retractable Technologies Inc, Orchestra Biomed Holdings, Inc. and Precision Optics Corporation, Inc. The side-by-side comparison below sets their revenue, margins and growth against Utah Medical Products Inc's.
When is Utah Medical Products Inc's next earnings date?
Around January 28, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Utah Medical Products Inc announces its own schedule.